Medication Pearl of the Day: Margetuximab (Margenza)
Indication: Margetuximab (Margenza)is a human epidermal growth factor receptor 2 (HER2)/neu receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received 2 or more prior anti-HER2 regimens, at least one of which was for metastatic disease.
- Dosing: Administer margetuximab as an intravenous infusion at 15 mg/kg over 120 minutes for the initial dose, then over a minimum of 30 minutes every 3 weeks for all subsequent doses.
- Dosage forms: Injection 250 mg/10 mL (25 mg/mL) in a single-dose vial.
- Adverse events: The most common adverse drug reactions (>10%) with margetuximab in combination with chemotherapy are fatigue/asthenia, nausea, diarrhea, vomiting, constipation, headache, pyrexia, alopecia, abdominal pain, peripheral neuropathy, arthralgia/myalgia, cough, decreased appetite, dyspnea, infusion-related reactions, palmar-plantar, and extremity pain.
- Warning: Monitor for signs and symptoms of infusion-related reactions. If a significant infusion-associated reaction occurs, slow or interrupt the infusion and administer appropriate medical therapies.
- Mechanism of action: Margetuximab binds to the extracellular domain of the HER2 protein. Upon binding to HER2-expressing tumor cells, margetuximab inhibits tumor cell proliferation, reduces shedding of the HER2 extracellular domain. and mediates antibody-dependent cellular cytotoxicity.
- Manufacturer: MacroGenics